The functions of the avian receptor activator of NF-κB ligand (RANKL) and its receptors, RANK and osteoprotegerin, are evolutionarily conserved

被引:20
|
作者
Sutton, Kate M. C. [1 ,2 ]
Hu, Tuanjun [1 ,2 ]
Wu, Zhiguang [1 ,2 ]
Siklodi, Botond [3 ]
Vervelde, Lonneke [1 ,2 ]
Kaiser, Pete [1 ,2 ]
机构
[1] Univ Edinburgh, Roslin Inst, Easter Bush EH25 9RG, Midlothian, Scotland
[2] Univ Edinburgh, R D SVS, Easter Bush EH25 9RG, Midlothian, Scotland
[3] CEVA Phylaxia Vet Biol Co Ltd, H-1107 Budapest, Hungary
来源
基金
英国生物技术与生命科学研究理事会;
关键词
Chicken; TNF superfamily; Cytokines; Pro-inflammatory; DC; Macrophages; TUMOR-NECROSIS-FACTOR; ALPHA-DEFICIENT MICE; TNF FAMILY-MEMBER; DENDRITIC CELLS; T-CELLS; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; IMMUNE-RESPONSE; TERMINAL KINASE; EXPRESSION;
D O I
10.1016/j.dci.2015.03.006
中图分类号
S9 [水产、渔业];
学科分类号
0908 ;
摘要
A new member of the chicken TNF superfamily has recently been identified, namely receptor activator of NF-kappa B ligand (RANKL), as have its signalling receptor, RANK, and its decoy receptor, osteoprotegerin (OPG). In mammals, RANKL and RANK are transmembrane proteins expressed on the surface of Th1 cells and dendritic cells (DC) respectively, whereas OPG is expressed as a soluble protein from osteoblasts and DC. Recombinant soluble chicken RANKL (chRANKL) forms homotrimers whereas chicken OPG (chOPG) forms homodimers, characteristic of these molecules in mammals. ChRANKL, chRANK and chOPG are expressed at the mRNA level in most tissues and organs. ChRANKL is transcriptionally regulated by Ca2+ mobilisation and enhances the mRNA expression levels of pro-inflammatory cytokines in bone marrow-derived DC (BMDC); this is inhibited by both chOPG-Fc and soluble chRANK-Fc. However, chRANKL does not enhance the expression of cell surface markers in either BMDC or BM-derived macrophages (BMM). Furthermore, chRANKL enhances the survival of APC similar to its mammalian orthologue. (C) 2015 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:170 / 184
页数:15
相关论文
共 50 条
  • [31] Serum osteoprotegerin but not receptor activator of NF-κB ligand correlates with Larsen score in rheumatoid arthritis
    Skoumal, M
    Kolarz, G
    Woloszczuk, W
    Hawa, G
    Klingler, A
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (02) : 216 - 217
  • [32] Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer
    Elfar, Gamal A.
    Ebrahim, Mohamed A.
    Elsherbiny, Nehal M.
    Eissa, Laila A.
    [J]. ONCOLOGY RESEARCH, 2017, 25 (04) : 641 - 650
  • [33] Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-κB (NF-κB) ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvarial bones
    Swanson, Charlotte
    Lorentzon, Mattias
    Conaway, H. Herschel
    Lerner, Ulf H.
    [J]. ENDOCRINOLOGY, 2006, 147 (07) : 3613 - 3622
  • [34] Osteoprotegerin reduces the serum level of receptor activator of NF-κB ligand derived from osteoblasts
    Nakamichi, Yuko
    Udagawa, Nobuyuki
    Kobayashi, Yasuhiro
    Nakamura, Midrori
    Yamamoto, Yohei
    Yamashita, Teruhito
    Mizoguchi, Toshihide
    Sato, Masahiro
    Mogi, Makio
    Penninger, Josef M.
    Takahashi, Naoyuki
    [J]. JOURNAL OF IMMUNOLOGY, 2007, 178 (01): : 192 - 200
  • [35] Circulating levels of osteoprotegerin and receptor activator of NF-κB ligand in patients with chronic renal failure
    Shaarawy, Mohamed
    Fathy, Shadia A.
    Mehany, Nagy L.
    Hindy, Odette W.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (11) : 1498 - 1503
  • [36] Expression of receptor activator of NF-κB ligand and osteoprotegerin in peripheral giant cell granulomas of the jaws
    Fanourakis, Galinos
    Lazaris, Andreas C.
    Krithinakis, Stylianos
    Tosios, Konstantinos I.
    Sklavounou, Alexandra
    Tseleni-Balafouta, Sofia
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2010, 39 (09) : 687 - 689
  • [37] The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation
    Salbach-Hirsch, Juliane
    Kraemer, Julia
    Rauner, Martina
    Samsonov, Sergey A.
    Pisabarro, M. Teresa
    Moeller, Stephanie
    Schnabelrauch, Matthias
    Scharnweber, Dieter
    Hofbauer, Lorenz C.
    Hintze, Vera
    [J]. BIOMATERIALS, 2013, 34 (31) : 7653 - 7661
  • [38] Receptor Activator of NF-κB Ligand (RANKL) is protective against hepatic ischemia/reperfusion injury
    Sakai, Nozomu
    Van Sweringen, Heather L.
    Tevar, Amit D.
    Edwards, Michael J.
    Lentsch, Alex B.
    [J]. FASEB JOURNAL, 2011, 25
  • [39] Expression of receptor activator of NF-κB ligand (RANKL) mRNA in human multiple myeloma cells
    Heider, U
    Zavrski, I
    Jakob, C
    Bängeroth, K
    Fleissner, C
    Langelotz, C
    Possinger, K
    Hofbauer, LC
    Viereck, V
    Sezer, O
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (08) : 469 - 474
  • [40] Expression, purification, and characterization of the human receptor activator of NF-κB ligand (RANKL) extracellular domain
    Willard, D
    Chen, WJ
    Barrett, G
    Blackburn, K
    Bynum, J
    Consler, T
    Hoffman, C
    Horne, E
    Iannone, MA
    Kadwell, S
    Parham, J
    Ellis, B
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2000, 20 (01) : 48 - 57